PeptiDream Inc. (4587.T)
JPY 2018.5
(1.74%)
JPY 2018.5
(1.74%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 17.21 Billion JPY | -6.91% |
| 2022 | 18.11 Billion JPY | 158.47% |
| 2021 | 7 Billion JPY | -26.46% |
| 2020 | 9.52 Billion JPY | 1341.52% |
| 2019 | 661.06 Million JPY | -88.12% |
| 2018 | 5.56 Billion JPY | 19.73% |
| 2017 | 4.64 Billion JPY | 31.46% |
| 2016 | 3.53 Billion JPY | 9.08% |
| 2015 | 3.24 Billion JPY | 84.93% |
| 2014 | 1.75 Billion JPY | 247.69% |
| 2013 | 504.13 Million JPY | 22.75% |
| 2012 | 410.69 Million JPY | 304.29% |
| 2011 | 101.58 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 28.48 Billion JPY | 1826.2% |
| 2024 Q1 | 1.47 Billion JPY | -50.52% |
| 2023 Q1 | 2.14 Billion JPY | -82.93% |
| 2023 Q2 | 1.81 Billion JPY | -15.67% |
| 2023 Q3 | 10.26 Billion JPY | 466.61% |
| 2023 Q4 | 2.98 Billion JPY | -70.9% |
| 2023 FY | 16.86 Billion JPY | -6.91% |
| 2022 FY | 18.11 Billion JPY | 158.47% |
| 2022 Q4 | 12.59 Billion JPY | 249.09% |
| 2022 Q2 | 1.02 Billion JPY | 1447.13% |
| 2022 Q1 | -76.01 Million JPY | -108.55% |
| 2022 Q3 | 3.6 Billion JPY | 252.23% |
| 2021 Q4 | 889.02 Million JPY | -78.73% |
| 2021 FY | 7 Billion JPY | -26.46% |
| 2021 Q2 | 2.09 Billion JPY | 119.27% |
| 2021 Q3 | 4.18 Billion JPY | 99.39% |
| 2021 Q1 | 956.19 Million JPY | -86.31% |
| 2020 Q1 | 55.02 Million JPY | 0.0% |
| 2020 FY | 9.52 Billion JPY | 1341.52% |
| 2020 Q4 | 6.98 Billion JPY | 2133.16% |
| 2020 Q3 | 312.73 Million JPY | -85.64% |
| 2020 Q2 | 2.17 Billion JPY | 3857.87% |
| 2019 Q1 | 598.78 Million JPY | -46.06% |
| 2019 Q2 | 3.58 Billion JPY | 499.22% |
| 2019 FY | 661.06 Million JPY | -88.12% |
| 2019 Q3 | 72.78 Million JPY | -97.97% |
| 2018 Q2 | 4.61 Billion JPY | 4284.13% |
| 2018 Q3 | 268.47 Million JPY | -94.18% |
| 2018 Q1 | -110.25 Million JPY | -127.72% |
| 2018 Q4 | 1.11 Billion JPY | 313.47% |
| 2018 FY | 5.56 Billion JPY | 19.73% |
| 2017 FY | 4.64 Billion JPY | 31.46% |
| 2017 Q4 | 397.78 Million JPY | 257.48% |
| 2017 Q3 | -252.59 Million JPY | -108.97% |
| 2017 Q2 | 2.81 Billion JPY | 10587.27% |
| 2017 Q1 | 26.34 Million JPY | -80.79% |
| 2016 FY | 3.53 Billion JPY | 9.08% |
| 2016 Q3 | 556.86 Million JPY | -54.38% |
| 2016 Q4 | 137.17 Million JPY | -75.37% |
| 2016 Q2 | 1.22 Billion JPY | -11.3% |
| 2016 Q1 | 1.37 Billion JPY | 213.49% |
| 2015 Q3 | 206.04 Million JPY | -87.02% |
| 2015 FY | 3.24 Billion JPY | 84.93% |
| 2015 Q2 | 1.58 Billion JPY | 7051.62% |
| 2015 Q1 | 22.19 Million JPY | -82.65% |
| 2015 Q4 | 438.94 Million JPY | 113.03% |
| 2014 Q1 | 45.13 Million JPY | -79.27% |
| 2014 Q4 | 127.9 Million JPY | 711.97% |
| 2014 Q3 | 15.75 Million JPY | -88.76% |
| 2014 Q2 | 140.18 Million JPY | 210.56% |
| 2014 FY | 1.75 Billion JPY | 247.69% |
| 2013 FY | 504.13 Million JPY | 22.75% |
| 2013 Q2 | 102.56 Million JPY | 0.0% |
| 2013 Q3 | 101.02 Million JPY | -1.5% |
| 2013 Q4 | 217.79 Million JPY | 115.57% |
| 2012 FY | 410.69 Million JPY | 304.29% |
| 2011 FY | 101.58 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | -815.258% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | -21341.384% |
| GNI Group Ltd. | 22.43 Billion JPY | 23.238% |
| Linical Co., Ltd. | 3.77 Billion JPY | -355.728% |
| Trans Genic Inc. | 2.24 Billion JPY | -665.527% |
| MEDINET Co., Ltd. | 98.25 Million JPY | -17425.056% |
| Soiken Holdings Inc. | 2.48 Billion JPY | -593.639% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | -1232.088% |
| AnGes, Inc. | -3.06 Billion JPY | 661.733% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 9788.787% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | -78.174% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | -3228.62% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | -15418.51% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | -1087.01% |
| CanBas Co., Ltd. | -984 Million JPY | 1849.87% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | -4295.917% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | -939.684% |
| Chiome Bioscience Inc. | 398.59 Million JPY | -4219.853% |
| Kidswell Bio Corporation | 1.03 Billion JPY | -1556.629% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | -56161.127% |
| Ribomic Inc. | -10.5 Million JPY | 164056.561% |
| SanBio Company Limited | -14.5 Million JPY | 118817.03% |
| Healios K.K. | 108 Million JPY | -15843.257% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 5049577.419% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 29261.532% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 1138904.101% |
| StemRIM | -44.34 Million JPY | 38925.493% |
| CellSource Co., Ltd. | 3.18 Billion JPY | -440.619% |
| FunPep Company Limited | -680.28 Million JPY | 2631.096% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -24764.575% |
| Stella Pharma Corporation | 217.29 Million JPY | -7824.011% |
| TMS Co., Ltd. | -6.95 Million JPY | 247851.338% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | -5373.888% |
| Cuorips Inc. | 9.63 Million JPY | -178684.321% |
| K Pharma,Inc. | 910 Million JPY | -1792.167% |
| Takara Bio Inc. | 25.45 Billion JPY | 32.362% |
| ReproCELL Incorporated | 1.1 Billion JPY | -1458.647% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | -1340.827% |
| StemCell Institute Inc. | 1.57 Billion JPY | -992.64% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | -933.05% |
| CellSeed Inc. | 107.15 Million JPY | -15968.982% |